NCT00242580 - A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

January 31, 2008

Conditions

Macular DegenerationChoroidal Neovascularization

Interventions

DRUG

Verteporfin photodynamic therapy

After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.

DRUG

Pegaptanib

Pegaptanib sodium 0.3 mg administered by intravitreal injection.

DRUG

Triamcinolone acetonide

Triamcinolone acetonide administered by intravitreal injection.

Trial Locations (1)

78793

Novartis Investigational Site, Austin